Riz

Cetirizine Hydrochloride

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic

Treatment option: Atopic Dermatitis, Dermatitis, Blocked Nose, Jock Itch, Hives, Fever, Rhinitis, Hay Fever

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Riz

What is Riz? Defining the Medicine

Property	Description
Active ingredient	Cetirizine Hydrochloride
Form	Tablet, Oral solution, Capsule
Pharmacological class	Antihistamine
ightarrow H1-receptor antagonist
Common use	Relief from allergic manifestations
Origin	Synthetic (Second-generation piperazine derivative)

Riz is a medicine whose active ingredient is Cetirizine Hydrochloride, which is a synthetic compound derived from hydroxyzine, classified as a second-generation piperazine derivative. This ingredient is supplied as a single-ingredient product, offered commonly in the tablet, oral solution, and syrup dosage form(s) for the standard oral route of administration. The compound is clinically recognized for its long-acting profile, distinguishing it from older, shorter-acting antihistamine agents.

Riz belongs to the Antihistamine pharmacological class, functioning precisely as a highly selective H1-receptor antagonist. The principal effects of the medicine are mediated via selective inhibition of peripheral H1 receptors. This mechanism allows Cetirizine Hydrochloride to be characterized as a selective peripheral H1-antagonist, a type of medicine developed to prioritize action outside of the central nervous system. The medicine is recognized for its role in modulating allergic symptoms by inhibiting late-phase inflammatory responses. It is noted that this medicine can interrupt not only the initial stages of an allergy but also subsequent, more sustained reactions.

The general purpose of Riz is to provide relief from allergic manifestations by counteracting the effects of the chemical substance histamine. Histamine is naturally released by the body and is responsible for triggering many allergic symptoms; by blocking the H1-receptors, Cetirizine Hydrochloride helps to manage this response. The benefit derived from this specific receptor blockade is the control and reduction of bothersome physical signs associated with an allergic episode, such as runny nose, watery eyes, sneezing, and itching, fulfilling its role as an effective anti-allergic agent. This profile enables it to be widely accessible, frequently available as an over-the-counter (OTC) medicine in various jurisdictions.

Regulatory References

FDA label for Cetirizine

What side effects are possible with Riz?

Possible Side Effects and Safety Information

The safety profile for Riz (risankizumab) is primarily characterized by the risk of infections and hypersensitivity reactions, both of which are officially designated as areas requiring caution.

Common and Less Common Reactions

The most frequently reported adverse reaction is Upper Respiratory Tract Infections (such as the common cold), which is classified as very common (affecting more than 1 in 10 people). Other common side effects (affecting between 1 in 10 and 1 in 100 people) include:

Headache
Fatigue
Injection site reactions (e.g., redness, pain, bruising)
Tinea infections (fungal skin infections)

Serious Safety Concerns

Serious Allergic Reactions

Immediate medical attention is required for signs of a serious allergic reaction (anaphylaxis or angioedema), which may include fainting, swelling of the face, throat, or lips, difficulty breathing, throat tightness, or a severe widespread skin rash/hives. Riz is strictly contraindicated in patients with a history of serious hypersensitivity to the drug or its components.

Risk of Infection

As a drug that works by modulating the immune system, Riz may lower the body's ability to fight off infections, potentially leading to serious infections (including opportunistic infections and tuberculosis). Before treatment begins, a patient must be tested for latent tuberculosis (TB) infection, and any active infection must be adequately treated before initiating the medication. Patients must be closely monitored for signs and symptoms of any new infection throughout the course of treatment. Additionally, non-live vaccines may be administered, but the use of live vaccines must be avoided during therapy.

Population-Specific Notes

Specific monitoring requirements are documented for patients being treated for inflammatory bowel disease (Crohn's disease or ulcerative colitis), which may include the monitoring of liver enzymes and bilirubin. The long-term safety profile has generally been consistent across approved indications.

Overdose and Emergency Response

Overdose with Riz (Cetirizine Hydrochloride) is documented by regulatory authorities to cause a profile of signs primarily involving the Central Nervous System (CNS). The most frequently observed manifestations include CNS depression, characterized by somnolence (drowsiness), sedation, confusion, fatigue, and headache, alongside signs of potential tremor and restlessness. Other systemic manifestations noted in official labeling include tachycardia (fast heart rate) and urinary retention. Severe outcomes, such as cardiac arrhythmia, may occur following massive ingestions, emphasizing the need for professional monitoring.

In case of a suspected or confirmed overdose, official labeling mandates that individuals seek immediate medical help or contact a Poison Control Center right away. Urgent assessment is required to manage the documented symptoms.

Management of Riz overdose is supportive and symptomatic because regulatory sources confirm no known specific antidote exists. For massive ingestions, measures such as administering activated charcoal may be considered by healthcare professionals. It is officially documented that the substance cannot be effectively removed by dialysis. In the pediatric population, overdose incidents are often observed to resolve spontaneously, with drowsiness and sedation being the primary effects noted.

Therapeutic Uses of Riz

What Riz Treats: Main Uses and Benefits

As a second-generation antihistamine, Riz is commonly used in clinical settings that involve acute or disruptive symptom patterns associated with allergic conditions. The medicine is applied across domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity.

Riz is generally used to help with symptomatic relief for allergic rhinitis (including hay fever and perennial forms) and chronic urticaria (hives). It helps manage symptom clusters that may become intense or disruptive, such as persistent sneezing, runny nose, and itchy eyes in respiratory allergies, as well as notable itching (pruritus) and the accompanying redness caused by wheals in skin reactions.

This provides support that helps ease the overall symptom burden, contributes to easing the overall symptom load during periods of heightened symptoms, and may assist with maintaining functional stability when these symptoms interfere with routine activities.

Quick Fact: Relief for Itching and Hives

Quick Fact: Relief for Chronic Itching and Urticaria Riz is commonly used in conditions characterized by periods of heightened symptoms involving the skin. It plays a role in managing notable pruritus (itching) and the appearance of raised wheals associated with hives, providing supportive relief when these symptoms interfere with routine activities.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Riz?

The population eligibility for using Riz (Cetirizine Hydrochloride) is strictly defined by government regulatory agencies based on hypersensitivity, age, and organ function. Riz is contraindicated and must not be used by patients with a known allergy to the active substance, to excipients in the specific formulation, or to chemically related compounds such as hydroxyzine or other piperazine derivatives.

Use is also contraindicated in patients with severe renal impairment (end-stage renal disease or CLcr le 10 mL/min), as the drug is primarily eliminated by the kidneys. For patients with moderate renal impairment, use is restricted and requires conditional dose management. No dose adjustment is generally needed for sole hepatic impairment, but caution is advised for combined hepatic and renal impairment.

Age and Physiological Restrictions

Category	Official Eligibility Status
Adults/Adolescents	Generally permitted under standard labeled conditions.
Children	Eligibility depends on formulation, with liquid forms approved for use as young as 6 months (US FDA) or 2 years (EU/other regions). The tablet form is not recommended for children under 6 years.
Pregnancy	Use is permitted only if clearly needed and benefits outweigh potential risks (formerly FDA Category B).
Lactation	Not recommended by some official labels as the drug is excreted in breast milk.

Specific official labeling also advises using Riz with caution in populations with predisposing factors for urinary retention or those with epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Riz (Cetirizine Hydrochloride) involving certain prescription medicines, alcohol, and food.

Pharmacokinetic and Pharmacodynamic Interactions

The most significant interactions involve changes to Cetirizine's plasma exposure and additive Central Nervous System (CNS) effects:

CNS Depressants and Alcohol: Co-administration with alcohol or other CNS depressants may lead to additive CNS depression, increasing the risk of reduced alertness and impairment of CNS performance. This is classified as a pharmacodynamic interaction.
Ritonavir: Co-administration results in a significant increase in Cetirizine exposure (42% increase in AUC) and a 53% decrease in Cetirizine clearance. This change is a documented pharmacokinetic interaction.
Theophylline: The simultaneous administration of 400 mg Theophylline once daily is documented to reduce Cetirizine clearance by approximately 16%, though Theophylline's own profile remains unaltered.

Mechanism of Action

Riz, which is Rizatriptan, functions as a serotonin receptor agonist. Its primary biological targets are the 5-HT1B and 5-HT1D receptor subtypes.

At the 5-HT1B receptors expressed on the smooth muscle of cerebral blood vessels, Rizatriptan binding and activation induces vasoconstriction, leading to a reduction in local cerebral blood flow. This receptor is coupled to a Gi/o protein, and its activation results in the inhibition of adenylyl cyclase, which subsequently decreases the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).

At the 5-HT1D receptors, which are located on presynaptic terminals of sensory neurons in the trigeminal nerve system, Rizatriptan acts as an agonist to inhibit the release of neuropeptides, including calcitonin gene-related peptide (CGRP). This presynaptic inhibition reduces the signaling of trigeminal sensory afferents. The combined system-level physiological consequence is the modulation of intracranial vascular tone and the suppression of peripheral nociceptive neurotransmitter release from the trigeminal pathway.

Dosage and Administration Information

Riz (Cetirizine Hydrochloride) is typically administered by the oral route as a tablet, capsule, or solution, with an Intravenous (IV) injection form also approved for specific acute care scenarios. The general administration frequency is once daily (qDay), aligning with its long-acting pharmacological characteristics.

The standard oral dosing for adults and adolescents (ge 12 years) is between 5 mg and 10 mg. A rigid procedural constraint is that the 10 mg dose is the maximum permitted in a 24-hour period. This dose can be taken with or without food at any time of day. When the IV form is administered, the 10 mg dose must be delivered as a slow intravenous push over a specific duration of 1 to 2 minutes and cannot be repeated within 24 hours.

Standard practice involves dose adjustments for specific patient demographics. For patients with moderate renal impairment, the oral dose must be reduced to 5 mg once daily. Similarly, a 5 mg daily starting dose is often considered for older adults. The administration duration is flexible, ranging from short-term for acute periods to continuous use for chronic conditions. Furthermore, the tablet form is not recommended for children under 6 years due to dose inflexibility. If a dose is missed, common practice is to take it when remembered, or skip it if the next scheduled dose is imminent, ensuring that a double dose is never taken.

Recent Clinical Evidence

Riz: Recent Clinical Evidence

Evidence for use in Allergic Rhinitis

Riz was studied in research exploring how symptoms change over time related to seasonal and perennial allergic rhinitis (hay fever). Research relies primarily on numerous short-term Randomized Controlled Trials (RCTs), often comparing the medicine against a placebo. Studies examined outcomes related to physical discomfort, monitoring changes in Total Symptom Scores (TSS) and Quality of Life (QOL) scales over observation periods. Findings generally describe patterns observed in the studies that involve research exploring episodic symptom changes. A Research Limitation Frame is that most definitive trials are short-term, meaning long-term outcomes are not well characterized in formal controlled studies. Data for older patients (aged 65 and over) remain insufficient to determine if their symptom patterns may differ significantly from younger adults.

Evidence for use in Chronic Urticaria (Hives)

For chronic urticaria, a condition characterized by fluctuating or episodic manifestations of hives and itching, research examined outcomes related to physical discomfort. The evidence base includes standard RCTs and Real-World Observational Studies. Studies focused on metrics like the Urticaria Activity Score (UAS7), which was used in research exploring short-term symptom changes by assessing the severity of weals and pruritus (itching). Specific research also investigated patients with refractory symptoms (symptoms not fully addressed by initial management), and research describes the observed symptom patterns in this subgroup.

Research Gaps and Remaining Uncertainty

Most core evidence supporting the clinical evaluation comes from short-term clinical trials. Information on durability of response over many months is primarily derived from observational settings evaluating daily-life functioning. Trials on refractory cases often had sample sizes that were modest, indicating that subgroup findings are uncertain. Also, differing metrics used across studies may introduce heterogeneity (variability) when synthesizing all available research.

Frequently Asked Questions (FAQ)

Common questions about Riz (FAQ)

Q: Can I take Riz for a regular headache or only for allergies?

According to official regulatory documents, Riz (Cetirizine) is indicated for the temporary relief of symptoms caused by hay fever or other upper respiratory allergies. Its recognized use is focused on treating allergic manifestations like sneezing, runny nose, and itching.

Q: What are the instructions if I miss a dose of Riz?

Official guidance generally suggests that if an oral dose is missed, a person may take it when remembered or skip it if the next scheduled dose is near. It is typically advised not to take a double dose. The regulatory text does not provide separate or specific guidance for a missed dose of the intravenous (IV) formulation.

Q: What is the primary mechanism by which Rizatriptan works to stop a migraine?

Rizatriptan is used specifically to treat acute migraine headaches. Official drug information indicates that it works by causing the blood vessels in the brain to narrow, which is thought to interrupt the migraine process. It is also described as inhibiting pain signals from being released in the nervous system.

Q: Which age group is the tablet formulation of Riz not recommended for?

Regulatory information states that the tablet formulation of Riz is not recommended for children under 6 years of age. The official label notes that for older adults (65 years and over), consultation with a healthcare professional may be necessary before use.

Q: Is there a generic version of Riz available?

Yes, the active ingredient in Riz, which is Cetirizine Hydrochloride, is widely available from various manufacturers. You may find the generic version offered in tablet and other common dosage forms.

Q: Does Riz affect the ability to drive or operate machinery?

Official product information cautions that Riz may cause drowsiness in some users. Official information suggests that due to the potential for this side effect, caution is generally advised when engaging in activities that require full alertness, such as driving a motor vehicle or operating machinery.

Q: Where is Riz (Cetirizine) primarily metabolized in the body?

According to official pharmacokinetic data, Riz (Cetirizine) is minimally metabolized, meaning it is broken down very little by the liver. The majority of the dose is excreted (removed from the body) unchanged, primarily by the kidney.

Q: What is the typical shelf life of an unopened Riz bottle?

Every Riz product is required by regulation to display a clear expiration date on its label. This date indicates the limit of time the medicine is guaranteed to be safe and maintain its full strength, provided it has been stored correctly in its original, tightly closed container.

How should Riz be stored and disposed of?

How to Store and Dispose of Riz (Cetirizine)

Official regulatory guidance specifies the exact conditions required for storing and disposing of Cetirizine Hydrochloride.

Storage Requirements

Cetirizine must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Temporary excursions up to 30°C (86°F) are permitted. The medicine must be kept in its original container and the container kept tightly closed.